ise and shine, everyone, another busy day is on the way. Yes, the peak vacation season is unfolding, but the world continues to spin, which means there is always much to do. This calls for a cup or three of stimulation — our flavor today is Southern pecan, for those keeping track — and, as always, we invite you to join us. Or hoist a bottle of water, if you prefer. As usual, here are some tidbits to help you along. Have a wonderful day and do keep in touch …

Novo Nordisk (NVO) may drop insulin prices in the U.S. next year as Sanofi (SNY) cuts prices of its own Lantus due to biosimilar competition, Pharmaphorum writes. Novo Nordisk expects average prices after rebates to be lower than levels in 2017 as prices of basal insulin are falling. Novo, Sanofi, and Eli Lilly (LLY) have been accused by lawmakers and in consumer lawsuits of collusion over high insulin prices. Novo maintains list prices have not kept up with rebates.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy